Please update your bookmark for the Blood Stocks Management Scheme website
The website address for the Blood Stocks Management Scheme, VANESA, will change in early 2017 to https://safe.nhsbt.nhs.uk/Vanesa so please update your bookmark.
You may also access the Blood Stocks Management Scheme website from the Bloodstocks website.
Sue Cotton, Blood Stocks Management Scheme Manager
Register for SHOT symposium 12 July 2017
Rothamsted Centre for Research and Enterprise
Lisa Parker, SHOT Administration Office Manager
Referring samples to RCI laboratories from patients receiving Daratumumab (anti-CD38) therapy for treatment of multiple myeloma
Please identify on the RCI referral form (FRM1597), any patients known to be treated with Daratumumab (anti-CD38).
Daratumumab (anti-CD38) is currently under trial in the UK for treatment of multiple myeloma.
Daratumumab does not interfere with ABO or Rh typing in pre-transfusion testing, but residual drug in patients' plasma can bind directly to CD38 on reagent red cells used in the laboratory for antibody screening or identification; or to donor red cells used for IAT crossmatch. This causes false positive antibody screen or identification results, typically with all cells tested. The false positive reactions can be abolished by the use of Dithiothreitol (DTT).
If necessary, consult with clinical staff at your own site, or your local trial site regarding the treatment of patients with multiple myeloma who have a positive antibody screen.
In some cases you will need to refer a sample to your RCI laboratory for investigation. Failure to identify patients undergoing treatment with Daratumumab, may lead to a delay in completing the investigation, as the presentation can mimic either auto antibodies or more typically, alloantibodies to high frequency antigens, and may result in no resolution being found. NHSBT scientists and clinicians are available to provide advice.
Dr Nay Win, Clinical Director - Diagnostics
Dr Mark Williams, National Head of RCI NHSBT